Skip to main content

Table 1 Clinical characteristics of rheumatoid arthritis patients recruited to the study

From: Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα

  Exploratory cohort Validation cohort
  (n = 10) (n = 85)
Sex (male/female) 1/9 11/74
Age, mean (range) 54.6 (38-74) 53.6 (24-72)
Disease duration (y), mean (range) 10.1 (2-23) 10.4 (1-36)
Smoking, number (%) 4 (40%) 23 (27.1%)
TJC, mean 13.7 ± 5.8 15.7 ± 4.6
SJC, mean 16.9 ± 6.5 11.5 ± 3.7
DAS28, mean 5.9 ± 0.7 5.7 ± 0.6
SDAI 39.7 ± 14.9 36.3 ± 10.9
HAQ 2.14 ± 0.5 2.1 ± 0.3
ESR (mm), mean 55 ± 18.62 55.9 ± 16.6
CRP (mg/dL), mean 3.6 ± 1.12 3.8 ± 2.1
Positive rheumatoid factor, n (%) 7 (70%) 60 (70.6%)
Positive anti-CCP antibody, n (%) 4 (40%) 59 (69.4%)
Medication, n (%)   
Infliximab 9 (90%) 46 (54.1%)
Etanercept 1 (10%) 24 (28.2%)
Adalimumab 0 15 (17.6%)
Corticoids, n(%) 4 (40%) 55 (64.7%)
Hydroxychloroquine, n (%) 3 (30%) 22 (25.9%)
Azathioprine, n (%) 0 (0%) 5 (5.9%)
Metotrexate, n (%) 7 (70%) 58 (68.2%)
Sulfasalazine, n (%) 1 (10%) 7 (8.2%)
Cyclosporine, n (%) 1 (10%) 2 (2.4%)
Leflunomide, n (%) 2 (20%) 33 (38.8%)
  1. TJC, tender joint count; SJC, swollen joint count; DAS28, disease activity score; SDAI, simplified disease activity index; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; anti-CCP, anti-cyclic citrullinated peptide antibodies.